An experimental oral small molecule called TOFA reduces body weight and liver inflammation in preclinical models by targeting energy and lipid metabolism directly, according to a study published in Science Advances in 2026. Researchers found that the compound lowers weight and improves metabolic markers in mice without suppressing appetite or causing the muscle loss typically associated with current incretin-based therapies.
Mechanisms of TOFA in Metabolic Regulation
The compound, formally designated as 5-tetradecyloxy-2-furansic acid, operates through a dual mechanism that sets it apart from traditional weight-loss drugs. According to the research team led by Prof. Anders Näär, TOFA inhibits two key enzymes—ACC1 and ACC2—that stimulate fat production in the liver, while simultaneously activating PPARα and PPARδ receptors to boost energy expenditure. In laboratory experiments, male mice fed a high-fat diet for seven weeks and subsequently treated with TOFA for four weeks lost an average of 18 percent of their body weight compared to a control group, despite consuming the same amount of food. The weight reduction consisted almost exclusively of body fat, preserving lean muscle mass.
Unlike earlier generations of ACC inhibitors, which frequently drove up blood lipid levels and elevated cardiovascular risks, TOFA administration reduced blood fats, particularly the unfavorable VLDL and LDL fractions. The study documented improvements in glycemic control, marked by lower blood sugar and reduced insulin levels. On a cellular level, the compound upregulated the PPAR network in the liver while downregulating the fat-production gene Srebp1, preventing the hypertriglyceridemia typically observed with single-target lipid-synthesis blockers.
Energy Expenditure and Liver Disease Models
Calorimetric measurements in specialized housing cages demonstrated that TOFA-treated mice burned approximately 18 percent more energy at normal room temperatures than control subjects. Because the energy increase narrowed to 4 percent under cold conditions—where brown adipose tissue naturally activates to generate heat—investigators concluded that the drug fundamentally reprograms systemic metabolism rather than simply stimulating thermogenesis. Core body temperatures remained stable throughout the treatment periods, with no indications of cardiac strain.
The evaluation extended to murine models of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Animals subjected to a liver-damaging diet for eight weeks followed by a four-week TOFA regimen shed an average of 8.7 percent of their body weight, alongside measurable reductions in hepatic inflammation and fibrosis markers. A second, more advanced disease model confirmed these histological and metabolic improvements following extended dietary and treatment protocols.
Combination Potential with Incretin Therapies
When researchers evaluated TOFA alongside established incretin-based anti-obesity drugs like semaglutide and tirzepatid, the combination produced synergistic outcomes. A 24-day co-administration regimen yielded greater weight reduction, superior glycemic control, and lower lipid profiles than any monotherapy alone. Furthermore, when treatments were withdrawn, mice treated with TOFA maintained their reduced body weight, whereas semaglutide-treated mice rapidly regained weight as their food intake rebounded.
The study authors emphasize that these findings remain strictly preclinical, derived entirely from animal models and cellular assays. Clinical trials in humans have not yet been conducted. Investigators plan to pursue clinical evaluations to determine whether TOFA can be safely translated into human medicine as a standalone therapy or as an adjunct to existing injectable weight-loss treatments.
Keep reading